Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.
Fc receptors
antibodies
immunotherapy
macrophages
tumour immunology
Journal
Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202
Informations de publication
Date de publication:
22 07 2022
22 07 2022
Historique:
received:
01
09
2021
revised:
26
10
2021
accepted:
19
11
2021
pubmed:
13
1
2022
medline:
27
7
2022
entrez:
12
1
2022
Statut:
ppublish
Résumé
The unmet clinical need for effective treatments in ovarian cancer has yet to be addressed using monoclonal antibodies (mAbs), which have largely failed to overcome tumour-associated immunosuppression, restrict cancer growth, and significantly improve survival. In recent years, experimental mAb design has moved away from solely targeting ovarian tumours and instead sought to modulate the wider tumour microenvironment (TME). Tumour-associated macrophages (TAMs) may represent an attractive therapeutic target for mAbs in ovarian cancer due to their high abundance and close proximity to tumour cells and their active involvement in facilitating several pro-tumoural processes. Moreover, the expression of several antibody crystallisable fragment (Fc) receptors and broad phenotypic plasticity of TAMs provide opportunities to modulate TAM polarisation using mAbs to promote anti-tumoural phenotypes. In this review, we discuss the role of TAMs in ovarian cancer TME and the emerging strategies to target the contributions of these cells in tumour progression through the rationale design of mAbs.
Identifiants
pubmed: 35020853
pii: 6433372
doi: 10.1093/cei/uxab020
pmc: PMC9307234
doi:
Substances chimiques
Antibodies, Monoclonal
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4-21Subventions
Organisme : Medical Research Council
ID : MR/L023091/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C30122/A11527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C30122/A15774
Pays : United Kingdom
Organisme : Cancer Research UK
ID : DCRPGF\100009
Pays : United Kingdom
Organisme : Department of Health
ID : CL-2020-17-002
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C604/A25135
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/V049445/1
Pays : United Kingdom
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Immunology.
Références
Cancer Discov. 2016 Apr;6(4):400-413
pubmed: 26896096
Neuropathol Appl Neurobiol. 2018 Feb;44(2):185-206
pubmed: 28767130
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:183-9
pubmed: 16515588
Oncotarget. 2017 Jun 13;8(24):39021-39032
pubmed: 28380460
Diagnostics (Basel). 2020 Mar 07;10(3):
pubmed: 32156035
Immunity. 2016 Mar 15;44(3):439-449
pubmed: 26982352
Springerplus. 2016 Jul 28;5(1):1197
pubmed: 27516935
Antibodies (Basel). 2020 Jul 20;9(3):
pubmed: 32698317
Technol Cancer Res Treat. 2013 Jun;12(3):259-67
pubmed: 23289476
Cancer Res. 2001 Oct 15;61(20):7556-62
pubmed: 11606394
Am J Pathol. 1997 May;150(5):1723-34
pubmed: 9137096
Clin Cancer Res. 2011 Jul 1;17(13):4451-61
pubmed: 21571868
EBioMedicine. 2019 May;43:67-81
pubmed: 30956175
Gynecol Oncol. 2008 May;109(2):215-9
pubmed: 18314181
Oncotarget. 2018 Jul 17;9(55):30552-30560
pubmed: 30093968
Ann Oncol. 2005 Dec;16(12):1889-97
pubmed: 16219625
Pathol Int. 2009 May;59(5):300-5
pubmed: 19432671
J Immunol. 2015 May 1;194(9):4379-86
pubmed: 25795760
J Clin Oncol. 2019 Jun 1;37(16):1380-1390
pubmed: 31002578
Nat Rev Cancer. 2008 Aug;8(8):579-91
pubmed: 18596824
J Clin Oncol. 2014 May 1;32(13):1302-8
pubmed: 24637997
Future Oncol. 2009 Nov;5(9):1429-40
pubmed: 19903070
Biochemistry. 1997 Dec 16;36(50):15568-78
pubmed: 9398285
Oncoimmunology. 2013 Jan 1;2(1):e23033
pubmed: 23483678
Lancet Oncol. 2021 Feb;22(2):267-276
pubmed: 33539744
Cancer Immunol Res. 2020 Mar;8(3):383-395
pubmed: 31924656
Cancer Res. 2017 Mar 1;77(5):1127-1141
pubmed: 28096174
Nat Commun. 2020 Jul 30;11(1):3801
pubmed: 32732879
PLoS One. 2015 Feb 06;10(2):e0118080
pubmed: 25658637
Cancer Res. 2007 Sep 15;67(18):8900-5
pubmed: 17875732
Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585
pubmed: 29158380
Nat Rev Immunol. 2008 Jan;8(1):34-47
pubmed: 18064051
Br J Cancer. 1994 Feb;69(2):342-6
pubmed: 8297732
J Clin Invest. 2019 May 20;129(7):2619-2628
pubmed: 31107246
Cancer Res. 2003 Aug 1;63(15):4490-6
pubmed: 12907622
Scand J Immunol. 2020 Jan;91(1):e12814
pubmed: 31419843
Commun Biol. 2020 Sep 22;3(1):524
pubmed: 32963283
Gynecol Oncol. 2014 Sep;134(3):478-85
pubmed: 25016924
Am J Obstet Gynecol. 1993 Feb;168(2):520-7
pubmed: 8438921
Oncogene. 2018 Sep;37(37):5127-5135
pubmed: 29789717
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
Cancer Cell. 2018 Apr 9;33(4):649-663.e4
pubmed: 29576375
J Clin Oncol. 2016 Jul 1;34(19):2271-8
pubmed: 27001568
Clin Cancer Res. 2015 Mar 15;21(6):1248-57
pubmed: 25589616
J Clin Invest. 1995 May;95(5):2391-6
pubmed: 7738202
Front Oncol. 2019 Jul 23;9:656
pubmed: 31396482
PLoS One. 2018 Jan 30;13(1):e0191972
pubmed: 29381731
JCI Insight. 2018 Dec 6;3(23):
pubmed: 30518684
J Transl Med. 2009 Jun 19;7:49
pubmed: 19545375
Oncol Lett. 2013 Jul;6(1):175-180
pubmed: 23946799
Semin Immunol. 2009 Oct;21(5):257-64
pubmed: 19540774
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
Clin Cancer Res. 2014 Apr 15;20(8):2192-204
pubmed: 24563479
J Clin Invest. 2013 Apr;123(4):1457-74
pubmed: 23454746
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33608377
Clin Cancer Res. 2012 Feb 1;18(3):771-82
pubmed: 22167410
Trends Mol Med. 2020 Jun;26(6):615-626
pubmed: 32470387
Ann Oncol. 2019 Aug 1;30(8):1381-1392
pubmed: 31114846
Antibodies (Basel). 2019 Feb 22;8(1):
pubmed: 31544825
Invest New Drugs. 2013 Jun;31(3):760-8
pubmed: 22907596
Cancers (Basel). 2020 Nov 15;12(11):
pubmed: 33203088
Int J Colorectal Dis. 2020 Jul;35(7):1203-1210
pubmed: 32303831
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32780724
Br J Cancer. 2017 Oct 24;117(9):1371-1382
pubmed: 28898232
J Ovarian Res. 2014 Feb 08;7:19
pubmed: 24507759
Cancer Lett. 2019 Aug 28;458:92-101
pubmed: 31129149
Cell. 2019 Sep 5;178(6):1509-1525.e19
pubmed: 31491389
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
Cell Rep. 2015 Apr 28;11(4):577-91
pubmed: 25892230
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Gynecol Oncol. 2016 Oct;143(1):27-34
pubmed: 27546885
J Hematol Oncol. 2020 May 5;13(1):45
pubmed: 32370812
Nat Struct Mol Biol. 2011 May;18(5):571-6
pubmed: 21516097
N Engl J Med. 2011 Dec 29;365(26):2484-96
pubmed: 22204725
Mol Oncol. 2014 Oct;8(7):1231-9
pubmed: 24816187
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50
pubmed: 23385782
Oncotarget. 2017 Aug 24;8(57):96496-96505
pubmed: 29228548
Int J Gynecol Cancer. 2017 Jan;27(1):50-58
pubmed: 27749456
Blood. 2007 Dec 15;110(13):4319-30
pubmed: 17848619
MAbs. 2015;7(2):303-10
pubmed: 25667985
Ann Oncol. 2015 Oct;26(10):2141-9
pubmed: 26216383
Cancer Cell. 2018 Apr 9;33(4):563-569
pubmed: 29634944
Nat Rev Immunol. 2008 Mar;8(3):205-17
pubmed: 18301424
J Exp Med. 2019 Mar 4;216(3):688-703
pubmed: 30710055
J Clin Oncol. 2003 Jan 15;21(2):283-90
pubmed: 12525520
J Clin Oncol. 2021 Jun 10;39(17):1842-1855
pubmed: 33891472
Int J Mol Sci. 2015 Feb 04;16(2):3391-404
pubmed: 25658794
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Cancer Treat Rev. 2020 Jun;86:102017
pubmed: 32335505
Clin Cancer Res. 2011 Sep 15;17(18):6083-96
pubmed: 21795409
PLoS One. 2012;7(12):e50946
pubmed: 23284651
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32819974
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31689243
Oncoimmunology. 2016 Mar 28;5(6):e1154250
pubmed: 27471625
Front Oncol. 2020 Feb 27;10:221
pubmed: 32175278
Front Oncol. 2017 Feb 22;7:24
pubmed: 28275576
Cancer Immunol Res. 2014 Nov;2(11):1051-8
pubmed: 25252722
Sci Rep. 2018 May 25;8(1):8171
pubmed: 29802255
Lancet Oncol. 2019 Jun;20(6):862-876
pubmed: 31076365
Breast Cancer Res Treat. 2011 Aug;128(3):703-711
pubmed: 20842526
Eur J Immunol. 2003 Apr;33(4):1030-40
pubmed: 12672069
J Clin Invest. 2012 Mar;122(3):787-95
pubmed: 22378047
Mol Oncol. 2012 Jun;6(3):360-9
pubmed: 22265591
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
Eur J Cancer. 2017 Jan;70:111-121
pubmed: 27914241
Semin Immunopathol. 2016 Sep;38(5):581-603
pubmed: 27225312
Int J Cancer. 2010 Nov 1;127(9):2209-21
pubmed: 20473913
Reproduction. 2011 Jun;141(6):821-31
pubmed: 21393340
Trends Mol Med. 2018 May;24(5):472-489
pubmed: 29655673
Cell Oncol (Dordr). 2012 Feb;35(1):9-18
pubmed: 21647742
Immunobiology. 2019 May;224(3):355-361
pubmed: 30926154
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
JCI Insight. 2018 May 17;3(10):
pubmed: 29769439
Cancers (Basel). 2018 Sep 29;10(10):
pubmed: 30274280
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Oncogene. 2019 Apr;38(16):2885-2898
pubmed: 30568223
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
Gynecol Oncol. 2015 Oct;139(1):10-6
pubmed: 26271155
Nat Rev Immunol. 2018 Mar;18(3):153-167
pubmed: 28990585
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
Clin Cancer Res. 1997 Jun;3(6):999-1007
pubmed: 9815777
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
J Exp Med. 2008 Jun 9;205(6):1261-8
pubmed: 18490490
Cancer Res. 2007 Jun 15;67(12):5708-16
pubmed: 17575137
Clin Cancer Res. 2017 Oct 1;23(19):5703-5710
pubmed: 28655795
Cell Rep. 2014 Aug 7;8(3):696-706
pubmed: 25088418